;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Tafinlar dabrafenib: Phase III data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Tafinlar dabrafenib (GSK2118436) Business: Cancer Molecular target: BRAF Description: Oral BRAF protein kinase inhibitor Indication: Treat unresectable or …

    Published on 7/21/2014
  • Tarceva erlotinib: Phase II data

    Genentech Inc., South San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Tarceva …

    Published on 7/21/2014
  • TC-1734: Development discontinued

    Targacept Inc. (NASDAQ:TRGT), Winston-Salem, N.C. Product: TC-1734, AZD3480 Business: Neurology Molecular target: Nicotinic acetylcholine receptor alpha(4)beta(2) Description: Neuronal nicotinic acetylcholine receptor …

    Published on 7/21/2014
  • TRV734: Phase I data

    Trevena Inc. (NASDAQ:TRVN), King of Prussia, Pa. Product: TRV734 Business: Neurology Molecular target: Mu opioid receptor (OPRM1) (MOR) Description: G protein-biased mu opioid receptor (OPRM1; MOR) ligand Indication: …

    Published on 7/21/2014
  • Yervoy ipilimumab: Phase III data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Yervoy ipilimumab (BMS-734016) Business: Cancer Molecular target: CTLA-4 (CD152) Description: Human mAb against CTLA-4 receptor Indication: Adjuvant treatment…

    Published on 7/21/2014
  • Yttrium-90-clivatuzumab tetraxetan: Final Phase Ib data

    Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Yttrium-90-clivatuzumab tetraxetan (Y-90 hPAM4) (formerly IMMU-107) Business: Cancer Molecular target: Mucin 1 (MUC1) (CD227) Description: Yttrium-90 …

    Published on 7/21/2014
  • 4SC-202: Phase I data

    4SC AG (Xetra:VSC), Planegg-Martinsried, Germany Product: 4SC-202 Business: Cancer Molecular target: Histone deacetylase 1 (HDAC1); Lysine-specific demethylase 1 (KDM1A) (LSD1) Description: Oral small molecule inhibitor…

    Published on 7/14/2014
  • A-101: Phase II data

    Aclaris Therapeutics Inc., Malvern, Pa. Product: A-101 Business: Dermatology Molecular target: NA Description: Undisclosed topical treatment Indication: Treat seborrheic keratosis Endpoint: Physician lesion assessment …

    Published on 7/14/2014
  • Abicipar pegol: Additional Phase II data

    Molecular Partners AG, Schlieren, Switzerland Allergan Inc. (NYSE:AGN), Irvine, Calif. Product: Abicipar pegol (AGN-150998, MP0112) Business: Ophthalmic Molecular target: Vascular endothelial growth factor A (VEGF-A) …

    Published on 7/14/2014
  • Aldoxorubicin: Additional Phase Ib/II data

    CytRx Corp. (NASDAQ:CYTR), Los Angeles, Calif. Product: Aldoxorubicin (formerly DOXO-EMCH, INNO-206) Business: Cancer Molecular target: DNA Description: 6-maleimidocaproyl hydrazone prodrug of doxorubicin Indication: …

    Published on 7/14/2014
  • Angiomax: Phase IV data

    The Medicines Co. (NASDAQ:MDCO), Parsippany, N.J. AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Angiomax ( Angiox - EU) bivalirudin Business: Cardiovascular Molecular target: Thrombin (Factor IIa) (F2) …

    Published on 7/14/2014
  • AuriPro: Phase III data

    Otonomy Inc., San Diego, Calif. Product: AuriPro (formerly OTO-201) Business: Infectious Molecular target: NA Description: Sustained-release gel formulation of ciprofloxacin Indication: Intraoperative treatment of …

    Published on 7/14/2014
  • BEMA Buprenorphine: Phase III data

    BioDelivery Sciences International Inc. (NASDAQ:BDSI), Raleigh, N.C. Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Product: BEMA Buprenorphine (EN3409) (formerly BEMA LA) Business: Neurology Molecular …

    Published on 7/14/2014
  • Cavatak: Updated Phase II data

    Viralytics Ltd. (ASX:VLA; OTCQX:VRACY), Pymble, Australia Product: Cavatak Business: Cancer Molecular target: Intercellular adhesion molecule-1 (ICAM-1) (CD54) Description: Coxsackievirus A21 (CVA21) Indication: Treat …

    Published on 7/14/2014
  • DGLA cream: Phase II data

    Dignity Sciences Ltd., Dublin, Ireland Product: DGLA cream (DS107E) Business: Dermatology Molecular target: NA Description: Topical formulation of a semi-synthetic derivative of dihomo-gamma-linolenic acid, an omega-6 …

    Published on 7/14/2014
  • Dupilumab: Phase IIa data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Dupilumab (REGN668, SAR231893) Business: Dermatology Molecular target: Interleukin-4 (IL-4) receptor…

    Published on 7/14/2014
  • Dupilumab: Phase IIa data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Dupilumab (REGN668, SAR231893) Business: Dermatology Molecular target: Interleukin-4 (IL-4) receptor…

    Published on 7/14/2014
  • Dupilumab: Phase IIb data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Dupilumab (REGN668, SAR231893) Business: Dermatology Molecular target: Interleukin-4 (IL-4) receptor…

    Published on 7/14/2014
  • Eteplirsen: Additional Phase IIb data

    Sarepta Therapeutics Inc. (NASDAQ:SRPT), Cambridge, Mass. Product: Eteplirsen (AVI-4658) Business: Musculoskeletal Molecular target: DNA Description: Phosphorodiamidate morpholino oligomer (PMO) targeting exon 51 …

    Published on 7/14/2014
  • Etirinotecan pegol: Additional Phase II data

    Nektar Therapeutics (NASDAQ:NKTR), San Francisco, Calif. Product: Etirinotecan pegol (NKTR-102) Business: Cancer Molecular target: Topoisomerase I (TOP1) Description: Topoisomerase I (TOP1) inhibitor-polymer conjugate …

    Published on 7/14/2014
  • GS-9973: Additional Phase II data

    Gilead Sciences Inc. (NASDAQ:GILD), Foster City, Calif. Product: GS-9973 Business: Cancer Molecular target: Spleen tyrosine kinase (SYK) Description: Oral spleen tyrosine kinase (SYK) inhibitor Indication: Treat …

    Published on 7/14/2014
  • Lucentis ranibizumab: Phase IIIb data

    Genentech Inc., South San Francisco, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Lucentis ranibizumab (RG3645) Business: Ophthalmic Molecular …

    Published on 7/14/2014
  • Nalbuphine ER: Phase I data

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Trevi Therapeutics Inc., New Haven, Conn. Product: Nalbuphine ER (T111) Business: Dermatology Molecular target: Mu opioid receptor (OPRM1) (MOR); Kappa …

    Published on 7/14/2014
  • Otezla apremilast: Phase III data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Product: Otezla apremilast (CC-10004) Business: Autoimmune Molecular target: Phosphodiesterase-4 (PDE-4); Interleukin-2 (IL-2) Description: Oral phosphodiesterase-4 (PDE-4) …

    Published on 7/14/2014
  • PBI-4050: Phase I data

    ProMetic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF), Laval, Quebec Product: PBI-4050 Business: Renal Molecular target: NA Description: Oral anti-fibrotic compound Indication: Treat diabetic patients with chronic kidney …

    Published on 7/14/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993